Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
NEW YORK, Aug. 16, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Intellipharmaceutics International Inc. ("Intellipharmaceutics") (NASDAQ:IPCI) securities between January 14, 2016 and July 26, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sbm/intellipharmaceutics-international-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Intellipharmaceutics failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); (2) the Company did not include abuse-deterrent studies conducted to support abuse-deterrent label claims related to abuse of the drug by various pathways; (3) the Company was not submitting sufficient data to support approval of the NDA; and (4) as a result, Defendants’ statements about Intellipharmaceutics’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Intellipharmaceutics you have until September 29, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/intellipharmaceutics-international-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
